|Awarded On||February 19, 2020|
|Title||Investigating the Role ofCD38 as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Don Gibbons|
|Cancer Sites||Lung and Bronchus|
*Pending contract negotiation
Lung cancer is an aggressive cancer that claims 160000 lives in the US annually. Our long-term goal is to develop treatment strategies that improve cure rates. To this end, we have been investigating immune therapy. Lung cancers recruit and activate diverse inflammatory cells, creating an immunosuppressive environment favoring growth and spread. We have developed genetic mouse models with the mutations found in human lung cancer for detailed study of tumor growth and response to immune therapies. As in many patients, targeting a molecule on cancer cells in these models that regulates killer T cell activity, called programmed death ligand 1 (PD-L1), can provide partial benefit. Unfortunately...